A trial to ascertain if providing a structured education programme on managing type 2 diabetes and maintaining a healthier lifestyle helps people with intellectual disabilities manage their blood sugar levels

The clinical and cost-effectiveness of the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) programme for adults with Intellectual Disability (ID) and Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83150600

Enrollment

450

Registered

2022-11-09

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine

Interventions

Design: This is a two-stage parallel group randomised trial with an internal pilot, economic evaluation, and process evaluation. In PICO terms: Population: 450 adults aged =18 years

mild/moderate ID and T2D Intervention: DESMOND-ID education programme in addition to Treatment As Usual (TAU) Comparator: TAU Primary outcome: Change in HbA1c from baseline to 6 months post-randomi

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with T2D 2. Aged =18 years 3. Mild/moderate ID as confirmed by health professional/medical records 4. Sufficient communication skills to engage in a group education programme 5. Able to give informed consent 6. Living in the community

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Severe/profound ID 3. Displaying severe challenging behaviour 4. Acute psychotic illness 5. Lack mental capacity to give consent

Design outcomes

Primary

Measure	Time frame
Change in HbA1c from baseline to 6 months post-randomisation measured using blood test	—

Secondary

Measure	Time frame
1. Change in HbA1c from baseline at 12 months (all participants) and 18 months (Internal Pilot participants only) measured using blood test At 6 and 12 months (all participants), and at 18 months (Internal Pilot participants only): 2. Metabolic and cardiovascular measures: Lipids (Total cholesterol, Low-density lipoprotein (LDL) cholesterol, High-density lipoprotein (HDL) cholesterol), estimated Glomerular Filtration Rate (eGFR), Diastolic and systolic blood pressure (mmHg); Weight (kg); Body Mass Index (kg/m²) 3. Illness perception measured using the Illness Perception Questionnaire Revised (IPQ) 4. Depression measured using the Glasgow Depression Scale 5. Health-related quality of life measured using EQ-5D 6. Health and social care service use and associated costs measured using ModRUM (Modular Resource Use Measure) 7. Intervention costs measured using ModRUM	—

Measure

Time frame

1. Change in HbA1c from baseline at 12 months (all participants) and 18 months (Internal Pilot participants only) measured using blood test At 6 and 12 months (all participants), and at 18 months (Internal Pilot participants only): 2. Metabolic and cardiovascular measures: Lipids (Total cholesterol, Low-density lipoprotein (LDL) cholesterol, High-density lipoprotein (HDL) cholesterol), estimated Glomerular Filtration Rate (eGFR), Diastolic and systolic blood pressure (mmHg); Weight (kg); Body Mass Index (kg/m²) 3. Illness perception measured using the Illness Perception Questionnaire Revised (IPQ) 4. Depression measured using the Glasgow Depression Scale 5. Health-related quality of life measured using EQ-5D 6. Health and social care service use and associated costs measured using ModRUM (Modular Resource Use Measure) 7. Intervention costs measured using ModRUM

—

Countries

England, Northern Ireland, Scotland, United Kingdom

Contacts

Public ContactPauline McElhill

DESMOND-ID@NICTU.hscni.net+44 (0)28 961 51447

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026